Drug Discovery Product Showcase

  1. End-To-End Capabilities 8/17/2023

    We have the expertise, technologies, and state-of-the-art facilities at ElevateBio BaseCamp® to deliver cell and gene therapies from concept through commercialization, all under a single roof, right from the start.

  2. Single-Use System For Clinical And Commercial Production Of LNPs 7/21/2023

    Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.

  3. Automated, Single-Use System For Clinical And Commercial LNP Production 7/21/2023

    The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.

  4. High Performance, Reliable, And Flexible Bioreactors 7/17/2023

    High performance, reliability, and flexibility define this next-generation single-use system.

  5. CHO Platform Service Package For Biopharmaceutical Cell Line Development 6/28/2023

    Learn how this CHO platform service package can help you rapidly progress from DNA to GMP cell bank (MCB | WCB) and overcome typical obstacles that can delay a first commercial manufacturing batch.

  6. Protein L Resin For Affinity Capture 5/3/2023

    MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.

  7. Resin Offering High Productivity And Robust Processes 5/3/2023

    MabSelect™ VL affinity resin uses a protein L ligand with strong affinity for the variable region of a human antibody’s kappa light chain. The resin offers high productivity and robust processes for affinity capture of bispecific antibodies and antibody fragments containing the kappa light chain and offers a good capture alternative for antibody variants that does not bind to protein A.

  8. Bionanoparticle Technology 4/24/2023

    Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.

  9. GMP Manufacturing 4/24/2023

    Nanoform’s GMP facility utilizes its award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology for the manufacture of API nanoparticles to GMP standards.

  10. Pharmaceutical Development 4/24/2023

    Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.